Beam Therapeutics Inc. (BEAM) fair value analysis
Nasdaq · Updated 2026-10-19
BEAM price how computed
Valuation status
No fair-value estimate yetBEAM has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BEAM yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $23.47
- Sector
- Healthcare
- 12-month range
- $20.60–$37.92
- Market cap
- $2.42B
- From 52-week high
- -38.1%
- Shares outstanding
- 103M
- Rank in Healthcare by quality score
- #179 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Beam Therapeutics Inc. is a biotechnology company that develops precision genetic medicines using base editing and prime editing technologies to treat serious diseases. The company is headquartered in Cambridge, Massachusetts and operates in the United States and internationally.
BEAM currently ranks #179 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.42B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $156M
- Net margin
- -54.7%
- EPS (TTM)
- $-0.86
- Gross margin
- 100.0%
- Debt / equity
- 0.23
- Revenue growth (3-yr avg)
- -32.4%
- Shares outstanding
- 103M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 43 · neutral
- 50-day average
- $26.26
- 200-day average
- $28.35
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-218.0%)
2026-03 ▲ beat (+9.9%)
2025-12 ▲ beat (+330.7%)
2025-09 ▼ miss (-8.9%)
2025-06 ▲ beat (+8.3%)
2025-03 ▼ miss (-6.0%)
2024-12 ▲ beat (+10.3%)
2024-09 ▲ beat (+0.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 2 hold · 0 sell (15 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $52.1
- Target vs last price
- +122.0%
What our data shows for BEAM
- Shares are trading in the lower third of their 12-month price range of $20.60–$37.92.
- The 14-day relative strength index sits at a neutral 43.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BEAM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BEAM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BEAM stock undervalued?
TickrTrends has no fair-value estimate for BEAM yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BEAM's TickrTrends verdict?
BEAM is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BEAM compare to other Healthcare stocks?
BEAM ranks #179 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BEAM overbought or oversold?
BEAM's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does BEAM report earnings next?
BEAM's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does BEAM usually beat earnings estimates?
Over its last 8 reported quarters BEAM beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BEAM?
Of 15 analysts covering BEAM, 13 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $52.1 (+122.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.